Page last updated: 2024-08-23

ursodeoxycholic acid and Impaired Glucose Tolerance

ursodeoxycholic acid has been researched along with Impaired Glucose Tolerance in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bisson, WH; Cai, J; Chen, B; Deng, Y; Gao, X; Ge, P; Gonzalez, FJ; Jiang, C; Krausz, KW; Lian, G; Liu, C; Liu, J; Nichols, RG; Patterson, AD; Rimal, B; Shi, J; Sun, L; Wang, G; Wang, X; Wu, Q; Wu, Y; Xia, J; Xie, C; Yun, C; Zhang, H; Zhang, S; Zhang, X	1

Other Studies

1 other study(ies) available for ursodeoxycholic acid and Impaired Glucose Tolerance

Article	Year
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nature medicine, 2018, Volume: 24, Issue:12 Topics: Bacteroides; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Gastrointestinal Microbiome; Gene Expression Regulation, Bacterial; Glucose Intolerance; Humans; Hyperglycemia; Metabolome; Metagenomics; Metformin; Obesity; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid	2018

Article

Year

Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.

Nature medicine, 2018, Volume: 24, Issue:12

Topics: Bacteroides; Bile Acids and Salts; Diabetes Mellitus, Type 2; Diet, High-Fat; Gastrointestinal Microbiome; Gene Expression Regulation, Bacterial; Glucose Intolerance; Humans; Hyperglycemia; Metabolome; Metagenomics; Metformin; Obesity; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid

2018